{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:49:56Z","timestamp":1792460996149,"version":"4.5.0"},"reference-count":120,"publisher":"National Institute for Health and Care Research","issue":"8","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["17\/10\/02"],"award-info":[{"award-number":["17\/10\/02"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"\n Background<\/jats:title>\n Rheumatoid arthritis is a chronic autoimmune disease that primarily causes inflammation, pain and stiffness in the joints. People with severe disease may be treated with biological disease-modifying anti-rheumatic drugs, including tumour necrosis factor-\u03b1 inhibitors, but the efficacy of these drugs is hampered by the presence of anti-drug antibodies. Monitoring the response to these treatments typically involves clinical assessment using response criteria, such as Disease Activity Score in 28 joints or European League Against Rheumatism. Enzyme-linked immunosorbent assays can also be used to measure drug and antibody levels in the blood. These tests may inform whether or not adjustments to treatment are required or help clinicians to understand the reasons for treatment non-response or a loss of response.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Systematic reviews were conducted to identify studies reporting on the clinical effectiveness and cost-effectiveness of using enzyme-linked immunosorbent assays to measure drug and anti-drug antibody levels to monitor the response to tumour necrosis factor-\u03b1 inhibitors [adalimumab (Humira\u00ae<\/jats:sup>; AbbVie, Inc., North Chicago, IL, USA), etanercept (Enbrel\u00ae<\/jats:sup>; Pfizer, Inc., New York, NY, USA), infliximab (Remicade\u00ae<\/jats:sup>, Merck Sharp & Dohme Limited, Hoddesdon, UK), certolizumab pegol (Cimzia\u00ae<\/jats:sup>; UCB Pharma Limited, Slough, UK) and golimumab (Simponi\u00ae<\/jats:sup>; Merck Sharp & Dohme Limited)] in people with rheumatoid arthritis who had either achieved treatment target (remission or low disease activity) or shown primary or secondary non-response to treatment. A range of bibliographic databases, including MEDLINE, EMBASE and CENTRAL (Cochrane Central Register of Controlled Trials), were searched from inception to November 2018. The risk of bias was assessed using the Cochrane ROBINS-1 (Risk Of Bias In Non-randomised Studies \u2013 of Interventions) tool for non-randomised studies, with adaptations as appropriate. Threshold and cost\u2013utility analyses that were based on a decision tree model were conducted to estimate the economic outcomes of adding therapeutic drug monitoring to standard care. The costs and resource use were considered from the perspective of the NHS and Personal Social Services. No discounting was applied to the costs and effects owing to the short-term time horizon of 18 months that was adopted in the economic analysis. The impact on the results of variations in testing and treatment strategies was explored in numerous clinically plausible sensitivity analyses.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Two studies were identified: (1) a non-randomised controlled trial, INGEBIO, that compared standard care with therapeutic drug monitoring using Promonitor\u00ae<\/jats:sup> assays [Progenika Biopharma SA (a Grifols\u2013Progenika company), Derio, Spain] in Spanish patients receiving adalimumab who had achieved remission or low disease activity; and (2) a historical control study. The economic analyses were informed by INGEBIO. Different outcomes from INGEBIO produced inconsistent results in both threshold and cost\u2013utility analyses. The cost-effectiveness of therapeutic drug monitoring varied, from the intervention being dominant to the incremental cost-effectiveness ratio of \u00a3164,009 per quality-adjusted life-year gained. However, when the frequency of testing was assumed to be once per year and the cost of phlebotomy appointments was excluded, therapeutic drug monitoring dominated standard care.<\/jats:p>\n <\/jats:sec>\n \n Limitations<\/jats:title>\n There is limited relevant research evidence and much uncertainty about the clinical effectiveness and cost-effectiveness of using enzyme-linked immunosorbent assay-based testing for therapeutic drug monitoring in rheumatoid arthritis patients. INGEBIO had serious limitations in relation to the National Institute for Health and Care Excellence scope: only one-third of participants had rheumatoid arthritis, the analyses were mostly not by intention to treat and the follow-up was 18 months only. Moreover, the outcomes might not be generalisable to the NHS.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Based on the available evidence, no firm conclusions could be made about the cost-effectiveness of therapeutic drug monitoring in England and Wales.<\/jats:p>\n <\/jats:sec>\n \n Future work<\/jats:title>\n Further controlled trials are required to assess the impact of using enzyme-linked immunosorbent assays for monitoring the anti-tumour necrosis factors in people with rheumatoid arthritis.<\/jats:p>\n <\/jats:sec>\n \n Study registration<\/jats:title>\n This study is registered as PROSPERO CRD42018105195.<\/jats:p>\n <\/jats:sec>\n \n Funding<\/jats:title>\n This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment<\/jats:italic>; Vol. 25, No. 8. See the NIHR Journals Library website for further project information.<\/jats:p>\n <\/jats:sec>","DOI":"10.3310\/hta25080","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T20:49:01Z","timestamp":1612817341000},"page":"1-248","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation"],"prefix":"10.3310","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2723-0802","authenticated-orcid":true,"given":"Irina A","family":"Tikhonova","sequence":"first","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK"},{"name":"Southampton Health Technology Assessments Centre, University of Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3985-986X","authenticated-orcid":true,"given":"Huiqin","family":"Yang","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0665-223X","authenticated-orcid":true,"given":"Segun","family":"Bello","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6390-9524","authenticated-orcid":true,"given":"Andrew","family":"Salmon","sequence":"additional","affiliation":[{"name":"Peninsula Collaboration for Health Operational Research and Development, University of Exeter Medical School, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0463-875X","authenticated-orcid":true,"given":"Sophie","family":"Robinson","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4386-2511","authenticated-orcid":true,"given":"Mohsen Rezaei","family":"Hemami","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7541-3027","authenticated-orcid":true,"given":"Sophie","family":"Dodman","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1977-6840","authenticated-orcid":true,"given":"Andriy","family":"Kharechko","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0949-3417","authenticated-orcid":true,"given":"Richard C","family":"Haigh","sequence":"additional","affiliation":[{"name":"Royal Devon & Exeter NHS Foundation Trust, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1487-277X","authenticated-orcid":true,"given":"Meghna","family":"Jani","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal & Dermatological Sciences, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3559-6660","authenticated-orcid":true,"given":"Timothy J","family":"McDonald","sequence":"additional","affiliation":[{"name":"Royal Devon & Exeter NHS Foundation Trust, Exeter, UK"},{"name":"University of Exeter Medical School, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5593-9777","authenticated-orcid":true,"given":"Martin","family":"Hoyle","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2021,2]]},"reference":[{"key":"key20210205110817775_ref1-bib1","volume-title":"Services for People with Rheumatoid Arthritis","author":"National Audit Office"},{"key":"key20210205110817775_ref1-bib2","volume-title":"Making a Diagnosis of Rheumatoid Arthritis","author":"Dickson"},{"key":"key20210205110817775_ref1-bib3","first-page":"551","article-title":"One year in review: the pathogenesis of rheumatoid arthritis","volume":"33","author":"Picerno","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"key20210205110817775_ref1-bib4","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.berh.2011.10.010","article-title":"Precipitating and perpetuating factors of rheumatoid arthritis immunopathology: linking the triad of genetic predisposition, environmental risk factors and autoimmunity to disease pathogenesis","volume":"25","author":"Scott","year":"2011","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"key20210205110817775_ref1-bib5","volume-title":"What is the Cause of Rheumatoid Arthritis? Non-Genetic Factors","author":"National Rheumatoid Arthritis Society"},{"key":"key20210205110817775_ref1-bib6","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.1002\/art.20621","article-title":"Do breast-feeding and other reproductive factors influence future risk of rheumatoid arthritis? Results from the Nurses\u2019 Health Study","volume":"50","author":"Karlson","year":"2004","journal-title":"Arthritis Rheum"},{"key":"key20210205110817775_ref1-bib7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1136\/ard.2008.096487","article-title":"Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies","volume":"69","author":"Sugiyama","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key20210205110817775_ref1-bib8","volume-title":"The Genetics of Rheumatoid Arthritis","author":"National Rheumatoid Arthritis Society"},{"key":"key20210205110817775_ref1-bib9","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.autrev.2018.05.009","article-title":"Are we really what we eat? Nutrition and its role in the onset of rheumatoid arthritis","volume":"17","author":"Philippou","year":"2018","journal-title":"Autoimmun Rev"},{"key":"key20210205110817775_ref1-bib10","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/rheumatology\/keh059","article-title":"Early Rheumatoid Arthritis Study Group (ERAS), UK. Orthopaedic intervention in early rheumatoid arthritis. Occurrence and predictive factors in an inception cohort of 1064 patients followed for 5 years","volume":"43","author":"James","year":"2004","journal-title":"Rheumatology"},{"key":"key20210205110817775_ref1-bib11","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1093\/rheumatology\/kex352","article-title":"Improved flare and remission pattern in rheumatoid arthritis over recent decades: a population-based study","volume":"56","author":"Raheel","year":"2017","journal-title":"Rheumatology"},{"key":"key20210205110817775_ref1-bib12","unstructured":"National Institute for Health and Care Excellence (NICE). Rheumatoid Arthritis in Adults: Management. London: NICE; 2018. URL: www.nice.org.uk\/guidance\/ng100 (accessed October 2018)."},{"key":"key20210205110817775_ref1-bib13","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key20210205110817775_ref1-bib14","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/rheumatology\/41.7.793","article-title":"The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century","volume":"41","author":"Symmons","year":"2002","journal-title":"Rheumatology"},{"key":"key20210205110817775_ref1-bib15","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1093\/rheumatology\/33.8.735","article-title":"The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register","volume":"33","author":"Symmons","year":"1994","journal-title":"Br J Rheumatol"},{"key":"key20210205110817775_ref1-bib16","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1136\/annrheumdis-2018-213378","article-title":"Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"77","author":"Kearsley-Fleet","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"key20210205110817775_ref1-bib17","unstructured":"Gavan S. An Economic Evaluation of a Biomarker Test to Stratify Treatment for Rheumatoid Arthritis. PhD thesis. Manchester: University of Manchester; 2017."},{"key":"key20210205110817775_ref1-bib18","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1093\/rheumatology\/key013","article-title":"Rheumatoid arthritis and excess mortality: down but not out. A primary care cohort study using data from Clinical Practice Research Datalink","volume":"57","author":"Abhishek","year":"2018","journal-title":"Rheumatology"},{"key":"key20210205110817775_ref1-bib19","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1136\/ard.2005.043158","article-title":"Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register","volume":"65","author":"Hyrich","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"key20210205110817775_ref1-bib20","volume-title":"The Economic Burden of Rheumatoid Arthritis","author":"National Rheumatoid Arthritis Society"},{"key":"key20210205110817775_ref1-bib21","volume-title":"British National Formulary","author":"Joint Formulary Committee"},{"key":"key20210205110817775_ref1-bib22","first-page":"i71","article-title":"Adherence to biologic therapies in patients with inflammatory arthritis","volume":"54","author":"Brown","year":"2015","journal-title":"Rheumatology"},{"key":"key20210205110817775_ref1-bib23","unstructured":"National Institute of Health and Care Excellence (NICE). Adalimumab, Etanercept, Infliximab, Certolizumab Pegol, Golimumab, Tocilizumab and Abatacept for Rheumatoid Arthritis not Previously Treated with DMARDs or After Conventional DMARDs only have Failed. London: NICE; 2016. URL: www.nice.org.uk\/guidance\/ta375 (accessed July 2019)."},{"key":"key20210205110817775_ref1-bib24","volume-title":"NICE PathwaysRheumatoid Arthritis Overview.","author":"National Institute of Health and Care Excellence (NICE)"},{"key":"key20210205110817775_ref1-bib25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/BTT.S126854","article-title":"Focus on biosimilar etanercept \u2013 bioequivalence and interchangeability","volume":"12","author":"Cantini","year":"2018","journal-title":"Biologics"},{"key":"key20210205110817775_ref1-bib26","first-page":"S14","article-title":"The Health Assessment Questionnaire (HAQ)","volume":"23","author":"Bruce","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"key20210205110817775_ref1-bib27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"key20210205110817775_ref1-bib28","first-page":"100","article-title":"The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"key20210205110817775_ref1-bib29","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"key20210205110817775_ref1-bib30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/art.1780390105","article-title":"Comparison with the preliminary American College of Rheumatology and the World Health Organization\/International League Against Rheumatism Criteria","volume":"39","author":"van Gestel","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"20","key":"key20210205110817775_ref1-bib31","doi-asserted-by":"publisher","DOI":"10.3310\/hta22200","article-title":"What is the added value of ultrasound joint examination for monitoring synovitis in rheumatoid arthritis and can it be used to guide treatment decisions? A systematic review and cost-effectiveness analysis","volume":"22","author":"Simpson","year":"2018","journal-title":"Health Technol Assess"},{"key":"key20210205110817775_ref1-bib32","volume-title":"The DAS28 Score","author":"National Rheumatoid Arthritis Society"},{"key":"key20210205110817775_ref1-bib33","first-page":"93","article-title":"The Disease Activity Score and the EULAR response criteria","volume":"23","author":"Fransen","year":"2005","journal-title":"Clin Exp Rheumatol"},{"issue":"35","key":"key20210205110817775_ref1-bib34","doi-asserted-by":"publisher","DOI":"10.3310\/hta20350","article-title":"Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation","volume":"20","author":"Stevenson","year":"2016","journal-title":"Health Technol Assess"},{"key":"key20210205110817775_ref1-bib35","doi-asserted-by":"publisher","first-page":"e0205125","DOI":"10.1371\/journal.pone.0205125","article-title":"Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up","volume":"13","author":"Vogelzang","year":"2018","journal-title":"PLOS ONE"},{"key":"key20210205110817775_ref1-bib36","unstructured":"National Institute of Health and Care Excellence (NICE). Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a TNF Inhibitor. London: NICE; 2010."},{"key":"key20210205110817775_ref1-bib37","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1093\/rheumatology\/kew292","article-title":"A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice","volume":"55","author":"Jani","year":"2016","journal-title":"Rheumatology"},{"key":"key20210205110817775_ref1-bib38","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","volume-title":"The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions.","author":"Higgins","year":"2008"},{"key":"key20210205110817775_ref1-bib39","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLOS Med"},{"key":"key20210205110817775_ref1-bib40","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"key20210205110817775_ref1-bib41","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"key20210205110817775_ref1-bib42","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1136\/annrheumdis-2017-eular.4785","article-title":"Prospective, intervention, multicenter study of utility of biologic drug monitoring with respect to the efficacy and cost of adalimumab tapering in patients with rheumatic diseases: preliminary results of ingebio study","volume":"76","author":"Ucar","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key20210205110817775_ref1-bib43","article-title":"Prospective, intervention, multicenter, non-inferiority study of utility of therapeutic drug monitoring with respect to the efficacy and cost of adalimumab tapering in patients with rheumatic diseases","volume":"69","author":"Arango","year":"2017","journal-title":"Arthritis Rheum"},{"key":"key20210205110817775_ref1-bib44","doi-asserted-by":"publisher","first-page":"A227","DOI":"10.1136\/annrheumdis-2013-eular.717","article-title":"Therapeutic drug monitoring (TDM) in rheumatic day clinic enables to reduce pharmaceutical cost maintaining clinical efficacy","volume":"72","author":"Pascual-Salcedo","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20210205110817775_ref1-bib45","first-page":"835","article-title":"Prospective, intervention, multicenter study of utility of biologic drug monitoring with respect to the efficacy and cost of adalimumab tapering in patients with rheumatic diseases (34-week descriptive data) [abstract]","volume":"68","author":"Gorostiza","year":"2016","journal-title":"Arthritis Rheum"},{"key":"key20210205110817775_ref1-bib46","volume-title":"The Norwegian Drug Monitoring Study (NOR-DRUM).","author":"Haavardsholm","year":"2018"},{"key":"key20210205110817775_ref1-bib47","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1136\/annrheumdis-2012-202281","article-title":"Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study","volume":"72","author":"van der Maas","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20210205110817775_ref1-bib48","unstructured":"National Institute for Health and Care Excellence (NICE). Therapeutic Monitoring of TNF-alpha Inhibitors in Rheumatoid Arthritis. London: NICE; 2019. URL: www.nice.org.uk\/guidance\/dg36\/documents\/final-scope (accessed February 2020)."},{"key":"key20210205110817775_ref1-bib49","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1017\/S0266462305050324","article-title":"Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria","volume":"21","author":"Evers","year":"2005","journal-title":"Int J Technol Assess Health Care"},{"key":"key20210205110817775_ref1-bib50","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2165\/00019053-200624040-00006","article-title":"Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment","volume":"24","author":"Philips","year":"2006","journal-title":"PharmacoEconomics"},{"key":"key20210205110817775_ref1-bib51","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1136\/annrheumdis-2012-eular.1832","article-title":"Evaluating the cost-effectiveness of personalized treatment with adalimumab using serum drug level and anti-adalimumab antibodies in rheumatoid arthritis patients","volume":"71","author":"Krieckaert","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20210205110817775_ref1-bib52","first-page":"S779","article-title":"Evaluating the cost-effectiveness of personalized treatment with adalimumab using serum drug levels in rheumatoid arthritis patients","volume":"64","author":"Krieckaert","year":"2012","journal-title":"Arthritis Rheum-Us"},{"key":"key20210205110817775_ref1-bib53","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1136\/annrheumdis-2013-204101","article-title":"Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects","volume":"74","author":"Krieckaert","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20210205110817775_ref1-bib54","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2147\/BTT.S96982","article-title":"Cost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF-\u03b1 blockers","volume":"10","author":"Laine","year":"2016","journal-title":"Biologics"},{"key":"key20210205110817775_ref1-bib55","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"key":"key20210205110817775_ref1-bib56","volume-title":"Guideline for Cost-Of-Illness Study; Methods and Guideline-Rates for Economic Evaluations in Health Care. Guideline for Cost-Of-Illness Study","author":"Oostenbrink","year":"2000"},{"key":"key20210205110817775_ref1-bib57","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/annrheumdis-2012-202545","article-title":"Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective","volume":"72","author":"Vincent","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20210205110817775_ref1-bib58","volume-title":"Terveydenhuollon yksikk\u00f6kustannukset Suomessa vuonna 2006","author":"Hujanen","year":"2008"},{"issue":"14","key":"key20210205110817775_ref1-bib59","doi-asserted-by":"publisher","DOI":"10.3310\/hta15140","article-title":"Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation","volume":"15","author":"Malottki","year":"2011","journal-title":"Health Technol Assess"},{"key":"key20210205110817775_ref1-bib60","unstructured":"Department of Health and Social Care (DHSC). NHS Reference Costs 2015\u201316. London: DHSC; 2016."},{"key":"key20210205110817775_ref1-bib61","volume-title":"Ensuring the Value of Clinical Commissioning Group (CCG) Commissioned Biologics Medicines \u2013 Biologics Value Tariff Agreement.","author":"NHS Lambeth Clinical Commissioning Group"},{"key":"key20210205110817775_ref1-bib62","volume-title":"Regional Medicines Optimisation Committee Briefing Best Value Biologicals: Adalimumab Update 3","author":"NHS England","year":"2018"},{"key":"key20210205110817775_ref1-bib63","volume-title":"Commissioning Framework for Biological Medicines (Including Biosimilar Medicines).","author":"NHS England and NHS Improvement","year":"2017"},{"key":"key20210205110817775_ref1-bib64","volume-title":"Medicines Optimisation Dashboard","author":"NHS Business Services Authority"},{"key":"key20210205110817775_ref1-bib65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40744-017-0055-5","article-title":"bDMARD dose reduction in rheumatoid arthritis: a narrative review with systematic literature search","volume":"4","author":"Verhoef","year":"2017","journal-title":"Rheumatol Ther"},{"key":"key20210205110817775_ref1-bib66","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-eular.1854","article-title":"Association between flare and radiographic progression in patients with rheumatoid arthritis [abstract]","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key20210205110817775_ref1-bib67","volume-title":"BSRBR-RA Database","author":"University of Manchester"},{"key":"key20210205110817775_ref1-bib68","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1093\/rheumatology\/kew053","article-title":"The BSRBR-RA at 15 years","volume":"55","author":"Dennison","year":"2016","journal-title":"Rheumatology"},{"key":"key20210205110817775_ref1-bib69","unstructured":"National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology Appraisal 2013. London: NICE; 2013. URL: www.nice.org.uk\/process\/pmg9\/chapter\/foreword (accessed December 2018)."},{"key":"key20210205110817775_ref1-bib70","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3899\/jrheum.121521","article-title":"Flares in rheumatoid arthritis: frequency and management. A report from the BRASS registry","volume":"41","author":"Bykerk","year":"2014","journal-title":"J Rheumatol"},{"key":"key20210205110817775_ref1-bib71","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.3899\/jrheum.090369","article-title":"Developing a standardized definition for disease \u2018flare\u2019 in rheumatoid arthritis (OMERACT 9 Special Interest Group)","volume":"36","author":"Bingham","year":"2009","journal-title":"J Rheumatol"},{"key":"key20210205110817775_ref1-bib72","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s13075-015-0730-2","article-title":"Disease flares in rheumatoid arthritis are associated with joint damage progression and disability: 10-year results from the BeSt study","volume":"17","author":"Markusse","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"key20210205110817775_ref1-bib73","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1136\/annrheumdis-2017-eular.3066","article-title":"Clinical activity, ultrasound assessment and drug monitoring in rheumatoid arthritis patients receiving anti-TNF-alpha therapy with extended interval of administration","volume":"76","author":"Senabre Gallego","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key20210205110817775_ref1-bib74","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.berh.2015.05.009","article-title":"Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis","volume":"29","author":"Lahiri","year":"2015","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"key20210205110817775_ref1-bib75","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1093\/rheumatology\/kew200","article-title":"Risk of Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis treated with inhibitors of tumour necrosis factor \u03b1: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"55","author":"Bruce","year":"2016","journal-title":"Rheumatology"},{"key":"key20210205110817775_ref1-bib76","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"BSRBR Control Centre ConsortiumDrug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key20210205110817775_ref1-bib77","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1136\/annrheumdis-2016-209322","article-title":"Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key20210205110817775_ref1-bib78","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008794.pub2","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","volume":"2","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"key20210205110817775_ref1-bib79","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","article-title":"Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"386","author":"Singh","year":"2015","journal-title":"Lancet"},{"key":"key20210205110817775_ref1-bib80","first-page":"36","article-title":"Practices for managing a flare of long-standing rheumatoid arthritis: survey among French rheumatologists","volume":"23","author":"Maravic","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"key20210205110817775_ref1-bib81","volume-title":"Unit Costs of Health and Social Care 2017","author":"Curtis","year":"2017"},{"key":"key20210205110817775_ref1-bib82","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2165\/00019053-200523060-00007","article-title":"The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK","volume":"23","author":"Barbieri","year":"2005","journal-title":"PharmacoEconomics"},{"key":"key20210205110817775_ref1-bib83","doi-asserted-by":"publisher","first-page":"R56","DOI":"10.1186\/ar4491","article-title":"Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs","volume":"16","author":"Radner","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"key20210205110817775_ref1-bib84","volume-title":"Archived Reference Costs","author":"NHS Improvment"},{"key":"key20210205110817775_ref1-bib85","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s10198-011-0360-9","article-title":"The impact of using different tariffs to value EQ-5D health state descriptions: an example from a study of acute cough\/lower respiratory tract infections in seven countries","volume":"14","author":"Oppong","year":"2013","journal-title":"Eur J Health Econ"},{"key":"key20210205110817775_ref1-bib86","volume-title":"CCEMG\u2013EPPI-Centre Cost Converter","author":"The Campbell and Cochrane Economics Methods Group (CCEMG) and the Evidence for Policy and Practice Information and Coordinating Centre (EPPI Centre)"},{"key":"key20210205110817775_ref1-bib87","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/S0140-6736(12)61811-X","article-title":"Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial","volume":"381","author":"Smolen","year":"2013","journal-title":"Lancet"},{"key":"key20210205110817775_ref1-bib88","unstructured":"National Institute for Health and Care Excellence (NICE). Tocilizumab for the Treatment of Rheumatoid Arthritis [TA247]. London: NICE; 2012. URL: www.nice.org.uk\/guidance\/ta247 (accessed December 2018)."},{"key":"key20210205110817775_ref1-bib89","volume-title":"Remicade 100mg Powder for Concentrate for Solution for Infusion.","author":"Datapharm"},{"key":"key20210205110817775_ref1-bib90","unstructured":"National Institute for Health and Care Excellence (NICE). Therapeutic Monitoring of TNF-alpha Inhibitors in Crohn\u2019s Disease (LISA-TRACKER ELISA Kits, IDKmonitor ELISA Kits, and Promonitor ELISA kits) [DG22]. London: NICE; 2016. URL: www.nice.org.uk\/guidance\/dg22 (accessed December 2018)."},{"key":"key20210205110817775_ref1-bib91","unstructured":"National Institute for Health and Care Excellence (NICE). Infliximab, Adalimumab And Golimumab for Treating Moderately to Severely Active Ulcerative Colitis after the Failure of Conventional Therapy [TA329]. London: NICE; 2015. URL: www.nice.org.uk\/guidance\/ta329 (accessed December 2018)."},{"key":"key20210205110817775_ref1-bib92","volume-title":"Get a Price.","author":"Royal Mail"},{"key":"key20210205110817775_ref1-bib93","article-title":"Economic impact of decreasing adalimumab and etanercept doses and drug monitoring in patients with rheumatoid arthritis in clinical remission: preliminary study from a local biologics unit [abstract]","volume":"67","author":"Rosas","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key20210205110817775_ref1-bib94","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/rheumatology\/kev298","article-title":"Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up","volume":"55","author":"Chen","year":"2016","journal-title":"Rheumatology"},{"key":"key20210205110817775_ref1-bib95","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1093\/rheumatology\/keh703","article-title":"Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis","volume":"44","author":"Kobelt","year":"2005","journal-title":"Rheumatology"},{"key":"key20210205110817775_ref1-bib96","doi-asserted-by":"publisher","first-page":"e019146","DOI":"10.1136\/bmjopen-2017-019146","article-title":"Trends and determinants of length of stay and hospital reimbursement following knee and hip replacement: evidence from linked primary care and NHS hospital records from 1997 to 2014","volume":"8","author":"Burn","year":"2018","journal-title":"BMJ Open"},{"key":"key20210205110817775_ref1-bib97","volume-title":"National Schedule of Reference Costs Year: 2010\u201311 NHS Trusts and PCTS Combined HRG Data","author":"NHS","year":"2013"},{"key":"key20210205110817775_ref1-bib98","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1136\/ard.2007.084459","article-title":"Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate","volume":"68","author":"Wells","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key20210205110817775_ref1-bib99","doi-asserted-by":"publisher","first-page":"e000382","DOI":"10.1136\/rmdopen-2016-000382","article-title":"DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable","volume":"3","author":"Fleischmann","year":"2017","journal-title":"RMD Open"},{"key":"key20210205110817775_ref1-bib100","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1136\/annrheumdis-2012-201918","article-title":"Healthcare service utilisation costs are reduced when rheumatoid arthritis patients achieve sustained remission","volume":"72","author":"Barnabe","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20210205110817775_ref1-bib101","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1002\/art.22943","article-title":"Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients","volume":"56","author":"Aletaha","year":"2007","journal-title":"Arthritis Rheum"},{"key":"key20210205110817775_ref1-bib102","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.jval.2014.11.002","article-title":"Mapping from the Health Assessment Questionnaire to the EQ-5D: the impact of different algorithms on cost-effectiveness results","volume":"17","author":"Pennington","year":"2014","journal-title":"Value Health"},{"key":"key20210205110817775_ref1-bib103","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/art.22885","article-title":"Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis","volume":"57","author":"Bansback","year":"2007","journal-title":"Arthritis Rheum"},{"key":"key20210205110817775_ref1-bib104","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1002\/art.10471","article-title":"Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis","volume":"46","author":"Kobelt","year":"2002","journal-title":"Arthritis Rheum"},{"key":"key20210205110817775_ref1-bib105","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/rheumatology\/36.5.551","article-title":"Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D)","volume":"36","author":"Hurst","year":"1997","journal-title":"Br J Rheumatol"},{"key":"key20210205110817775_ref1-bib106","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1093\/rheumatology\/kes400","article-title":"The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis","volume":"52","author":"Hern\u00e1ndez Alava","year":"2013","journal-title":"Rheumatology"},{"key":"key20210205110817775_ref1-bib107","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.rbr.2012.12.001","article-title":"A systematic review of the influence of anti-TNF on infection rates in patients with rheumatoid arthritis","volume":"53","author":"Goh","year":"2013","journal-title":"Rev Bras Reumatol"},{"key":"key20210205110817775_ref1-bib108","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/rheumatology\/kes305","article-title":"The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment","volume":"52","author":"Listing","year":"2013","journal-title":"Rheumatology"},{"key":"key20210205110817775_ref1-bib109","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13075-016-0950-0","article-title":"EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden","volume":"18","author":"G\u00fclfe","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"key20210205110817775_ref1-bib110","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1136\/ard.2008.103473","article-title":"Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden","volume":"69","author":"G\u00fclfe","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key20210205110817775_ref1-bib111","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1093\/rheumatology\/ket239","article-title":"Undifferentiated spondyloarthritis vs ankylosing spondylitis and psoriatic arthritis: a real-life prospective cohort study of clinical presentation and response to treatment","volume":"52","author":"Paramarta","year":"2013","journal-title":"Rheumatology"},{"key":"key20210205110817775_ref1-bib112","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1002\/art.39169","article-title":"Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis","volume":"67","author":"Jani","year":"2015","journal-title":"Arthritis Rheum"},{"key":"key20210205110817775_ref1-bib113","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1136\/annrheumdis-2015-208849","article-title":"High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort","volume":"76","author":"Jani","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key20210205110817775_ref1-bib114","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1136\/annrheumdis-2017-211781","article-title":"Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial","volume":"77","author":"l\u2019Ami","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"key20210205110817775_ref1-bib115","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","article-title":"Populating an economic model with health state utility values: moving toward better practice","volume":"13","author":"Ara","year":"2010","journal-title":"Value Health"},{"key":"key20210205110817775_ref1-bib116","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1136\/annrheumdis-2018-eular.1946","article-title":"The association of biologic drug-levels with infection risk: results from the british society for rheumatology biologics register for rheumatoid arthritis","volume":"77","author":"Jani","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"key20210205110817775_ref1-bib117","volume-title":"NICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials","author":"Dias","year":"2014"},{"key":"key20210205110817775_ref1-bib118","volume-title":"Rheumatology Biologic Drug Monitoring Recommendations.","author":"NHS Greater Glasgow and Clyde"},{"key":"key20210205110817775_ref1-bib119","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1136\/annrheumdis-2013-204172","article-title":"Key findings towards optimising adalimumab treatment: the concentration-effect curve","volume":"74","author":"Pouw","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20210205110817775_ref1-bib120","doi-asserted-by":"publisher","first-page":"172","DOI":"10.4172\/2329-6887.1000172","article-title":"Dose-tapering of TNF inhibitors in daily rheumatology practice enables the maintenance of clinical efficacy while improving cost-effectiveness","volume":"3","author":"Pascual-Salcedo","year":"2015","journal-title":"Pharmacovigilance"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2035847","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta25080\/hta25080.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2035847","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T15:28:26Z","timestamp":1692113306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta25080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":120,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["10.3310\/hta25080"],"URL":"https:\/\/doi.org\/10.3310\/hta25080","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"7-2008","name":"contractual_start_date","label":"Contractual start date","group":{"name":"article_history","label":"Article History"}},{"value":"1-2019","name":"editorial_review_begun","label":"Editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"10-2019","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}